Total Payments
$76,653
2024 Payments
$3,512
Companies
34
Transactions
165
Medicare Patients
46,313
Medicare Billing
$3.9M
Payment Breakdown by Category
Other$66,588 (86.9%)
Food & Beverage$5,686 (7.4%)
Consulting$2,800 (3.7%)
Travel$1,534 (2.0%)
Education$44.73 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,088 | 29 | 86.2% |
| Food and Beverage | $5,686 | 114 | 7.4% |
| Consulting Fee | $2,800 | 8 | 3.7% |
| Travel and Lodging | $1,534 | 8 | 2.0% |
| Honoraria | $500.00 | 1 | 0.7% |
| Education | $44.73 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29,776 | 33 | $0 (2024) |
| Amgen Inc. | $28,950 | 42 | $0 (2024) |
| PFIZER INC. | $14,670 | 19 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $694.64 | 4 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $462.04 | 12 | $0 (2024) |
| Abbott Laboratories | $268.35 | 4 | $0 (2024) |
| iRhythm Technologies, Inc. | $193.78 | 2 | $0 (2023) |
| Boston Scientific Corporation | $189.75 | 3 | $0 (2023) |
| BIOTRONIK INC. | $152.00 | 2 | $0 (2023) |
| Merck Sharp & Dohme LLC | $148.60 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,512 | 32 | E.R. Squibb & Sons, L.L.C. ($2,983) |
| 2023 | $6,737 | 40 | E.R. Squibb & Sons, L.L.C. ($5,849) |
| 2022 | $3,324 | 8 | E.R. Squibb & Sons, L.L.C. ($3,022) |
| 2021 | $134.31 | 2 | iRhythm Technologies, Inc. ($119.81) |
| 2020 | $2,916 | 3 | Amgen Inc. ($2,905) |
| 2019 | $12,064 | 15 | Amgen Inc. ($8,466) |
| 2018 | $27,757 | 31 | Amgen Inc. ($17,235) |
| 2017 | $20,209 | 34 | PFIZER INC. ($10,379) |
All Payment Transactions
165 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $31.46 | General |
| Category: Medical Device | ||||||
| 12/04/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Cardiology | ||||||
| 11/20/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.24 | General |
| Category: Cardiovascular | ||||||
| 11/13/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/23/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Cardiology | ||||||
| 09/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,232.00 | General |
| Category: Cardiovascular | ||||||
| 08/28/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $121.84 | General |
| Category: Cardiovascular | ||||||
| 08/27/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/19/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: Diabetes | ||||||
| 07/31/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Cardiology | ||||||
| 07/24/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.61 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 07/10/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/30/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $6.86 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 05/29/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/08/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 05/08/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Cardiology | ||||||
| 05/02/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $14.75 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/17/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/10/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 03/27/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: Not Applicable | ||||||
| 03/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: DIABETES | ||||||
| 03/13/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 66 | 13,217 | 19,685 | $2.9M | $1.1M |
| 2022 | 67 | 11,567 | 19,684 | $2.7M | $958,182 |
| 2021 | 62 | 11,301 | 18,645 | $2.6M | $997,921 |
| 2020 | 57 | 10,228 | 14,621 | $2.5M | $889,662 |
Total Patients
46,313
Total Services
72,635
Medicare Billing
$3.9M
Procedure Codes
264
All Medicare Procedures & Services
264 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 2,810 | 3,833 | $835,594 | $341,932 | 40.9% |
| 78431 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | Office | 2023 | 58 | 58 | $255,548 | $119,335 | 46.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 599 | 636 | $302,736 | $88,153 | 29.1% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 175 | 175 | $176,750 | $56,844 | 32.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 253 | 646 | $96,254 | $40,440 | 42.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 246 | 274 | $113,710 | $37,461 | 32.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 321 | 321 | $107,214 | $36,782 | 34.3% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 58 | 116 | $92,568 | $36,291 | 39.2% |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 2023 | 175 | 350 | $82,600 | $30,902 | 37.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 529 | 549 | $82,350 | $28,547 | 34.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 149 | 596 | $73,308 | $25,559 | 34.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 2,957 | 4,105 | $34,165 | $25,235 | 73.9% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 144 | 145 | $58,580 | $19,093 | 32.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,710 | 1,802 | $73,882 | $18,037 | 24.4% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 281 | 283 | $44,431 | $13,226 | 29.8% |
| 75571 | Ct scan of heart with evaluation of blood vessel calcium | Office | 2023 | 169 | 169 | $71,825 | $11,997 | 16.7% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 128 | 221 | $31,603 | $11,841 | 37.5% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 87 | 94 | $23,218 | $7,724 | 33.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 93 | 283 | $19,810 | $7,089 | 35.8% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 188 | 413 | $28,497 | $6,289 | 22.1% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 140 | 288 | $19,872 | $6,057 | 30.5% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Office | 2023 | 52 | 55 | $13,145 | $4,922 | 37.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 46 | 46 | $13,018 | $4,677 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 31 | 35 | $10,290 | $4,665 | 45.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 48 | $10,224 | $4,521 | 44.2% |
About Dr. Mark Ramos, M.D
Dr. Mark Ramos, M.D is a Cardiovascular Disease healthcare provider based in Sarasota, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336339811.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Ramos, M.D has received a total of $76,653 in payments from pharmaceutical and medical device companies, with $3,512 received in 2024. These payments were reported across 165 transactions from 34 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($66,088).
As a Medicare-enrolled provider, Ramos has provided services to 46,313 Medicare beneficiaries, totaling 72,635 services with total Medicare billing of $3.9M. Data is available for 4 years (2020–2023), covering 264 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Sarasota, FL
- Active Since 07/31/2007
- Last Updated 10/18/2024
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1336339811
Products in Payments
- ELIQUIS (Drug) $42,578
- Repatha (Biological) $28,925
- LifeVest (Device) $694.64
- XARELTO (Drug) $462.04
- BIOMONITOR (Device) $152.00
- VERQUVO (Drug) $148.60
- CARDIOMEMS (Device) $140.67
- CoreValve Evolut (Device) $136.97
- Pentaray (Device) $125.00
- ZIO Patch (Device) $119.81
- GENERAL - THERAPIES (Device) $115.94
- AUSTEDO (Drug) $109.67
- Mitra Clip system (Device) $103.70
- LEQVIO (Drug) $98.69
- ZIO XT Patch (Device) $73.97
- OPTIMIZER (Device) $69.79
- (CK7) Extended Holter (Device) $65.58
- Cook Medical Zilver PTX (Device) $60.96
- EVKEEZA (Biological) $50.33
- VYNDAQEL (Drug) $49.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Sarasota
Dr. Mahfouz El Shahawy, Md, MD
Cardiovascular Disease — Payments: $135,512
Cardiovascular Disease $135,512
Hakim Morsli, Md, MD
Cardiovascular Disease — Payments: $120,552
Cardiovascular Disease $120,552
Dr. Elmer Arne, D.o, D.O
Cardiovascular Disease — Payments: $113,478
Cardiovascular Disease $113,478
Smriti Banthia, M.d, M.D
Cardiovascular Disease — Payments: $31,106
Cardiovascular Disease $31,106
Edward Bermudez, M.d, M.D
Cardiovascular Disease — Payments: $11,024
Cardiovascular Disease $11,024
Brett Milford, D.o, D.O
Cardiovascular Disease — Payments: $9,864
Cardiovascular Disease $9,864